Copyright ©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Figure 1
Figure 1 Barcelona Clinic Liver Cancer staging and treatment strategy[9]. BCLC: Barcelona Clinic Liver Cancer; PS: Performance status; TACE: Transarterial chemoembolization.
Figure 2
Figure 2 Hong Kong Liver Cancer prognostic classification scheme[10]. HKLC: Hong Kong Liver Cancer; LT: Liver transplantation; OS: Overall survival; PS: Performance status; TACE: Transarterial chemoembolization; EVM: Extrahepatic vascular invasion/metastasis.
Figure 3
Figure 3 Contraindications for conventional transarterial chemoembolisation[26].
Figure 4
Figure 4 Proposed treatment algorithm for the repetition of conventional transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. Response defined according to modified RECIST criteria. CR: Complete response; CT: Computed tomography; cTACE: Conventional TACE; EHS: Extrahepatic spread; HCC: Hepatocellular carcinoma; MRI: Magnetic resonance imaging; PD: Progressive disease; PR: Partial response; PVT: Portal vein thrombosis; RECIST: Response Evaluation Criteria In Solid Tumours; SD: Stable disease; TACE: Transarterial chemoembolization.
Figure 5
Figure 5 Diagram to define untreatable tumor progression[29]. CR: Complete response; PR: Partial response; HCC: Hepatocellular carcinoma.
Figure 6
Figure 6 APASL guideline on the treatment algorithm for hepatocellular carcinoma[8]. RFA: Radiofrequency ablation; HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.